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Abstract
Introduction
Serum N-glycans have been identified as putative biomarkers for numerous diseases. The
impact of different serum sample tubes and processing methods on N-glycan analysis has
received relatively little attention. This study aimed to determine the effect of different sam-
ple tubes and processing methods on the whole serum N-glycan profile in both health and
disease. A secondary objective was to describe a robot automated N-glycan release, label-
ing and cleanup process for use in a biomarker discovery system.
Methods
25 patients with active and quiescent inflammatory bowel disease and controls had three
different serum sample tubes taken at the same draw. Two different processing methods
were used for three types of tube (with and without gel-separation medium). Samples were
randomised and processed in a blinded fashion. Whole serum N-glycan release, 2-amino-
benzamide labeling and cleanup was automated using a Hamilton Microlab STARlet Liquid
Handling robot. Samples were analysed using a hydrophilic interaction liquid chromatogra-
phy/ethylene bridged hybrid(BEH) column on an ultra-high performance liquid chromatogra-
phy instrument. Data were analysed quantitatively by pairwise correlation and hierarchical
clustering using the area under each chromatogram peak. Qualitatively, a blinded assessor
attempted to match chromatograms to each individual.
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Results
There was small intra-individual variation in serum N-glycan profiles from samples collected
using different sample processing methods. Intra-individual correlation coefficients were be-
tween 0.99 and 1. Unsupervised hierarchical clustering and principal coordinate analyses
accurately matched samples from the same individual. Qualitative analysis demonstrated
good chromatogram overlay and a blinded assessor was able to accurately match individu-
als based on chromatogram profile, regardless of disease status.
Conclusions
The three different serum sample tubes processed using the described methods cause min-
imal inter-individual variation in serum whole N-glycan profile when processed using an au-
tomated workstream. This has important implications for N-glycan biomarker discovery
studies using different serum processing standard operating procedures.
Introduction
Serum whole N-glycan profiles have been investigated as putative biomarkers in many complex
immune disorders[1–6], including inflammatory bowel disease (IBD)[7,8] Both when seeking
to identify biomarkers and to investigate underlying biological differences between health and
disease, it is important to ensure observed changes are related to the disease and not a result of
the sampling method. This is especially important for large multi-centre studies where stan-
dard operating procedures may be different amongst members of the study consortium.
The vast number of commercially available serum collection tubes were previously consid-
ered to be inert sample carriers with no potential to effect the measured analyte[9]. However
several components of a serum collection tube can affect downstream assays; including the rub-
ber stopper, tube wall material, surfactants, clot activators, and gel separators[9]. The separator
gel acts a barrier to prevent contamination of the serum sample with cellular components, par-
ticularly erythrocytes. The presence of a gel separation medium is known to interfere with
some but not all analytes, including hormones and drug levels [10,11]. Although data on the ef-
fect of gel on glycan analysis is lacking, gel can cause interference with the routine analytic
techniques used to profile serum N-glycans including mass spectrometry and HPLC[12]. Addi-
tionally, the time taken to allow the sample to clot and conditions of pre-processing (tempera-
ture, centrifugation speed) may also effect analytical assays[13,14]. A study by Hsieh et al
demonstrated diverse changes in the serum proteome using MALDI TOF mass spectrometry
following changes in sample handling, prolonged clotting time (1 versus 24 hours) and storage
temperature (4°C versus room temperature)[15]. The authors attributed changes to continued
cellular metabolism, cellular lysis and consequent release of breakdown products and degrada-
tion products from the clot itself[15].
In the development of biomarkers, the first stage involves biomarker discovery[16]. To en-
sure the success of a putative biomarker, this first stage of discovery should be carefully per-
formed to ensure markers are a result of the disease and not sampling factors. To limit the
potential impact of human error, robot automation has been developed for the release, labeling
and cleanup of glycans[17]. Critically for widespread biomarker utilization, automation may
allow complex analytical techniques such as glycan profiling to become high-throughput[18].
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The aim of this study was to determine the effect of different sample tubes and processing
method on the whole serum N-glycan profile in health and disease. A secondary objective was
to describe a robot automated N-glycan release, labeling and cleanup process for use in a bio-
marker discovery system.
Materials and Methods
Patient recruitment
Suitable IBD patients were prospectively recruited from gastroenterology clinic and endoscopy
lists. Symptomatic controls consisted of patients undergoing investigations for suspected IBD,
but following radiological/endoscopic investigations were found not to have IBD.
Serum sample collection and initial processing
Blood sample collection was undertaken at the same time for research and clinical samples to
minimize patient discomfort. A Greiner 21Gauge butterfly needle with 30cm safety tube with
Luer lock device was used for venipuncture. The following tubes were taken from the same pa-
tient at the same draw: Tube 1–3.5ml vacuette plastic SST II Advance tube with gel separator,
clot activator, and BD Hemograd closure (BD, no 367956), Tube 2–2.5ml Z serum clot activa-
tor vacuette tube with gel separator (Greiner, no 454243) and Tube 3- 9ml Z Serum clot acti-
vated vacuette (No gel, Greiner, no 455092). Serum tubes were taken before other clinical and
research samples to prevent reagent contamination from other blood tubes (e.g. EDTA)[19].
Tubes were processed according to Table 1. Serum was aliquoted into 500μL screw cap tubes
and stored at -80°C.
Ethics statement
The Tayside Committee on Medical Ethics B (Ninewells Hospital, Dundee, NHS Tayside, Scot-
land) granted approval for this study with all patients and controls giving written, informed
consent (LREC 06/S1101/16, LREC 2000/4/192).
Robot Automation
The sample processing for this was automated using the Hamilton Microlab STARlet liquid
handling robot and is summarized in Fig 1.
Table 1. Serum Tube types and Processingmethods (RT = Room Temperature).
Tube Primary
tube
material
Gel
separator
Clot
activator
Minimum clotting
time (minutes)/
temperature (°C)
Centrifuge
speed (g)
Centrifuge
time (minutes)
Centrifuge
Temp (°C)
Total
processing time
(minutes)
Tube 1 BD
gel
Plastic Acrylic
based gel
Spray
Dried
60/4 2,500g 15 4 60–360
Tube 2
Greiner gel
Plastic Gel
unknown
type
Silica 30/ RT 2,000g 10 18 30–360
Tube 3
Greiner
plain
Plastic None Silica 60/4 2,500g 15 4 60–360
doi:10.1371/journal.pone.0123028.t001
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Step 1 and 2: Glycoprotein denaturation and N-glycan release
Ten microliters of each serum sample was aliquoted into a skirted 96 well PCR plate (4titude,
4ti-0960). The 96-well PCR plate was sealed with a pierce foil seal (4titude, 4ti-0531) and incu-
bated at 100°C for 2 minutes. The pierce foil seal was carefully removed and to each sample
was added 7.5 μL of de-ionised water and mixed. Reaction buffer x5 (5 μL, QAbio) and 1.25 μL
of Denaturation solution (1 Molar β-mecaptoethanol and 2% SDS, QAbio) were added to each
sample. The 96-well PCR plate was sealed with a pierce foil seal, samples mixed on a plate-
shaker for 1–2 minutes, and centrifuged briefly to collect samples in the bottom of the wells.
Samples were incubated for 10 minutes at 100°C. The samples were then allowed to cool to
room temperature and the pierce foil seal carefully removed. To each sample was added
1.25 μL of Triton X, followed by 1 μL (2 μL diluted 1:1 with de-ionised water) of PNGase F
(QAbio). The plate was again sealed with a pierce foil seal, mixed using the plate shaker, and
centrifuged briefly. The sample was then incubated overnight at 37°C in the oven (17 hours +/-
1 hour). The pierce foil seal was carefully removed and the 96-well PCR plate of samples was
placed in a rotary speed vac (room temp, no heat, 10 mBar, Thermo Savant) for 70 minutes to
dry down the samples completely.
Fig 1. Biomarker discovery systemworkflow. (SPE = solid phase extraction, UHPLC = Ultra high performance liquid chromatography)
doi:10.1371/journal.pone.0123028.g001
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Step 3: N-glycan clean-up
To the dried-down samples was added 20 μL of 1% formic acid (100 μL of formic acid in
9900 μL of water) followed by incubation for 50 minutes at room temperature. A Protein Bind-
ing Membrane (PBM) plate (LC-PBM-96, Ludger Ltd, UK) was washed with methanol
(100 μL) and de-ionised water (300 μL). After each wash a vacuum was applied (−0.1 to −0.2
bar), using the integrated Hamilton vacuum manifold, to elute the wash through the mem-
brane. The acidified sample was then transferred to the PBM plate. The initial PCR sample
plate was washed with 100 μL of de-ionized water and transferred to the PBM plate. The PCR
sample plate wash step was repeated once more and transferred to the PBM plate. A vacuum
(−0.1 to −0.3 bar) was applied to elute the acidified sample and washings through the PBM
plate and the eluent was collected within a 2 mL deep well collection plate (Ludger Ltd). The
samples were then transferred back to a non-skirted 96 well PCR plate (4titude, 4ti-0710) and
dried down again using a speed vac for 7±1 hours (room temp, no heat, 10 mBar, Thermo
Savant).
Step 4: N-Glycan labeling
The 2-AB labeling solution was prepared by adding 150 μL of DMSO/glacial acetic acid mix
(Ludger Ltd) to the vial of 2-AB/2PB reductant (2-aminobenzamide, 2-picoline borane, Ludger
Ltd). The solution was mixed until all the 2-AB/2PB reductant has dissolved. 10 μL of water
was added to each of the dried down samples, followed by 10 μL of labeling reagent. The sam-
ple PCR plate was sealed with a pierce foil seal, mixed on a sample shaker, briefly centrifuged,
and then incubated in an oven at 65 °C for 60 minutes. The sample was then cooled to room
temperature.
Step 5: SPE sample cleanup using HILIC (hydrophilic liquid interaction
chromatography)
A HILIC method was performed using LC-T1 cartridges (Ludger Ltd) placed into a 96-well
base plate (Ludger Ltd) placed upon the integrated Hamilton vacuum manifold. The LC-T1
cartridges were initially washed with 1 mL of water, and a vacuum applied (−0.1 to −0.2 bar) to
aid the elution of the wash through the cartridge. The same process was repeated with 1 ml of
96% acetonitrile. The samples were then transferred to the LC-T1 cartridge by the addition of
80 μL of acetonitrile to each sample, subsequent mixing of the samples followed by the transfer
of each diluted sample. 100 μL of acetonitrile was used to wash out the sample PCR plate and
transferred to the LC-T1 cartridges to ensure all the sample has been transferred to the car-
tridges. Initially, the acetonitrile is allowed to pass through the cartridges by gravity, and after
10 minutes a vacuum (−0.05 to −0.2 bar) is applied slowly to elute any remaining acetonitrile.
The cartridges are washed four times with 0.75 mL of 96% acetonitrile. After each wash addi-
tion, the 96% acetonitrile is left to elute under gravity for 4 minutes followed by a slow vacuum
(−0.05 to −0.2 bar) to elute any remaining 96% acetonitrile through the cartridges. A higher
vacuum (−0.2 to −0.5 bar) is used after the last wash elution step to remove as much 96% aceto-
nitrile as possible from the cartridges. A 2 mL 96 deep well collection plate (Ludger Ltd) was
then placed in the vacuum manifold under the cartridges. The 2-AB labelled N-glycans are
then eluted using 1 mL of water. A low vacuum setting (−0.05 bar, 10 seconds) was used to
start the elution followed by gravity elution for 15 minutes. A higher vacuum setting (−0.1
to −0.5 bar) was used to elute any remaining water from the cartridges.
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Step 6: Sample preparation for Ultra-high performance liquid
chromatography (UHPLC)
Samples were prepared for UHPLC by taking 110 μL of each 2-AB labelled glycan sample and
mixing with 390 μL of acetonitrile in a 96 deep well collection plate. The plate of samples was
covered with a pierce silicon sealing mat (Ludger Ltd) and placed directly in the UHPLC and
the samples analysed by HILIC-UHPLC using a Dionex UltiMate 3000 dual gradient system
UHPLC fitted with a BEH-Glycan 1.7 μm, 2.1 x 150 mm column (Waters, UK) at 40 °C and a
U3000 fluorescence detector set at excitation wavelength of 250 nm, emission wavelength of
428 nm, sensitivity = 8, lamp energy = high, controlled by Chromeleon data software version
6.8 (Dionex, USA).
A binary separation gradient was utilised where solvent A was 50 mM ammonium formate
made from LudgerSep N Buffer stock solution, pH4.4 (Ludger Ltd) and solvent B was acetoni-
trile (Acetonitrile 190 far UV/gradient quality; Romil #H049, Charlton Scientific, UK). Gradient
conditions were: 0 to 5 min, 24% A (0.4 mL/min); 5 to 38.5 min, 24 to 42% A (0.4 mL/min); 38.5
to 40.5 min, 42 to 60% A (0.4 to 0.25 mL/min); 40.5 to 42.5 min, 60% A (0.25 mL/min); 42.5 to
44.5, 60 to 24% A (0.25 mL/min); 44.5 to 50.5 min 24% A (0.25 mL/min); 50.5 to 51.5 min 24%
A (0.25 to 0.4 mL/min); 51.5 to 55.0 min 24% A (0.4 mL/min). Samples were injected directly
from the 96 deep well collection plate (22% aqueous/78% acetonitrile); injection volume 25 μL,
sample loop 50 μL size with 80% acetonitrile solvent used for UHPLC loop and needle washing
and to make up the injection volume to 50 μL for the U3000 partial mode injection setting. A
2-AB labelled glucose homopolymer (Ludger Ltd), was used as a system suitability standard as
well as an external calibration standard for GU allocation of the system.
Evaluation of automated N-glycan release protocol for use in a
biomarker discovery system
To assess the reproducibility of the newly developed automated N-glycan release protocol stan-
dard samples were processed in replicate. The plasma IgG N-glycan and whole plasma N-gly-
can profile was assessed using pooled human IgG glycan (G4386-10G, Sigma Aldrich, St Louis,
MO, USA) and pooled human plasma (P9523-5ML, Sigma Aldrich, St Louis, MO, USA)
respectively.
Quantitative correlation of samples
Peak identification and integration was performed using a custom algorithm written using R
3.1.1 (R Foundation for statistical computing, Vienna Austria). Raw chromatograms were ex-
ported from Chromeleon 7.1 (Dionex, USA). These were imported into R and then normalized
using the ChemoSpec package[20].The time axis of the chromatograms was aligned using the
highest peak as a reference. Peaks were identified using the first and second derivatives generated
using the glkerns function from the lokern package[21]. Peak positions were grouped across
using samples using hierarchical clustering, and peaks identified in at least 50% of samples were
kept, resulting in 42 peaks in the final dataset. Where a corresponding peak was not present in a
chromatogram, usually in regions of overlapping peaks, the surrounding peaks were used to esti-
mate its position. Peak area was then defined as the integral of the chromatogram between per-
pendicular lines dropped from the troughs. The peak identification was checked visually using
plots of the chromatograms and identified peaks. This method ensured that the same glycans
were quantified across all samples. The peak areas were normalized to the sum of all peaks.
Peaks within the neutral region of the chromatogram were also analysed separately and normal-
ized to the sum of just that subset. Variability of measured glycan levels was expressed as the
Serum Sample Tube & Processing Methodology and Serum N-Glycan Profiles
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average coefficient of variation using log-transformed data (CV ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
es
2
ln  1
p
). Pairwise com-
parisons between each sample were performed using Pearson’s correlation efficient. Hierarchical
clustering was performed using a distance metric of (1−|Pearson’s r|) and complete linkage.
Principal co-ordinate analysis was done using classical multidimensional scaling of the
(1−|Pearson’s r|) distance matrix. Demographic data were assumed to be non-normally dis-
tributed and Wilcoxon rank sum and Fisher’s exact test were used for comparisons. Differ-
ences at the level of individual glycans were assessed using analysis of variance of the log-
transformed data from individuals who had all three types of sample. The patient of origin
was used as a blocking variable.
Samples are named using an arbitrary letter for each participant, and a number for each
tube type, corresponding to the numbering in Table 1.
Qualitative assessment of serum samples
Chromatograms were assigned a numerical sample code, to which the assessor was blinded.
Chromatograms were classified into five groups according to the neutral/immunoglobulin-
type glycan section of the chromatograms (retention time 16 to 24 min) and their comparabili-
ty to the glycoprofile of glycans released from normal human gamma globulins (Sigma, UK).
The classes were ‘Normal’, identified as ‘NGal’ i.e. the serum neutral glycan region of the glyco-
profile was similar to the gamma globulin glycans with similar levels of biantennary, core fuco-
sylated glycan galactosylation, ‘Higher Galactosylation—HGal’ where biantennary core
fucosylated glycan galactosylation levels were higher than the gamma globulin levels, ‘Much
Higher Galactosylation—MHGal’, where biantennary core fucosylated glycan galactosylation
levels were much higher than the gamma globulin levels, ‘Lower Galactosylation—LGal’, where
biantennary core fucosylated glycan galactosylation levels were lower than the gamma globulin
levels and ‘Much Lower Galactosylation—MLGal’, where biantennary core fucosylated glycan
galactosylation levels were much lower than the gamma globulin levels. After classification into
the five galactosylation levels, chromatograms were visually matched.
Results
An automated N-glycan release protocol for use in a biomarker
discovery system
The first outcome of this study is the description of an automated N-glycan release, labeling
and clean-up process using a Hamilton Microlab STARlet liquid handling robot (Fig 1). Estab-
lished manual methods were optimized and adapted to produce an automated high throughput
(HTP) method in a 96 well plate based format. The reproducibility of the automated HTP
method was assessed by processing pooled samples of human serum IgG (repeated 48 times)
and whole plasma N-glycan (repeated 24 times) in replicate. For both pooled serum IgG glycan
and whole plasma N-glycan profiles the Pearson’s coefficient demonstrated a high level of cor-
relation of normalised peak areas (IgG glycans mean 0.9998 (range 0.9993–0.9999), Plasma
whole N-glycans mean 0.99991 (range 0.9996–0.99998)) (S1 Fig). The complete dataset is
available in S1 and S2 Data.
Patient demographics
The demographics of IBD patients and controls are displayed in Table 2. All patients were
White European ethnicity and ate a normal diet consisting of mixed meat, fish and vegetables.
The C-reactive protein was significantly higher in CD and symptomatic controls compared to
UC (vs. CD p = 0.01, vs. Symptomatic Control p = 0.04).
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Quantitative assessment of intra-individual variation in glycan profile
The complete chromatogram dataset is available in S1 Table, S2 Fig and S3 Data Chromato-
gram peaks were labeled in order from 1 to 42 (Fig 2). Glycan peaks were divided into neutral
(peaks 1 to 16) and total serum N-glycans (all peaks).
Pairwise comparison of samples demonstrated good intra-individual correlation (Pearson’s
coefficient 0.99–1.0) (S2 Table). Hierarchical clustering demonstrated a good ability to match
samples from the same individual (Fig 3). Complete correlation linkage using neutral glycans
paired all samples from the same individual in all cases, although one sample of three from in-
dividual A came from a different 6th order branch, but the same fifth order branch (Fig 3A).
Correlation linkage using total serum N-glycan structures paired samples from the same indi-
vidual slightly less well, with several samples from the same individual originating from slightly
different lower order branches, but the same higher order branches (Fig 3B). Clustering of sam-
ples was visualized using principal coordinate analysis with individual samples according to
disease status. Again, samples from the same individual appear to cluster together with the ex-
ception of individual A. There was no apparent clustering according to disease status (Fig 4).
Geometric mean peak areas and coefficients of variation (CV) for individual glycans can be
seen in Table 3. The CV for some of the smaller peaks was quite high, especially peaks 11 and
30, but was less than 6% for all peaks with at least 1% of the total area. Analysis of variance
(ANOVA) of the individual glycans revealed no differences that were significant by sample
type (minimum uncorrected p value 0.015, but 0.62 after Bonferroni correction for multiple
testing).
Qualitative assessment of intra-individual variation in glycan profile
By overlaying chromatograms from the 25 patients samples the blinded assessor was able to
correctly match patient samples in 18 of the 25 patients representing a 72% success rate
(Table 4).
Discussion
This study demonstrates minimal inter-individual variation in serum N-glycan profiling fol-
lowing three different methods of serum tube processing. Robot processing of samples in this
Table 2. Patient demographics (CD = Crohn’s disease, UC = ulcerative colitis, IQR = interquartile range, * =Wilcox sum rank test, † = χ2 with Yate’s
continuity correction, mg =milligrams, L = Litre).
Crohn’s disease
(n = 7)
CD vs
Symptomatic
control
Symptomatic control
(n = 7)
UC vs
Symptomatic
control
Ulcerative colitis
(n = 10)
Number of females (%) 2/7 (28.6) p = 1 † 4/7 (57.1) p = 1 † 3/10 (30)
Age (median, IQR) 28 (26.8–35.3) p = 0.9* 28 (26–31.5) p = 0.2* 50 (32.8–59.5)
Current or ex-smoker at
time of sampling (%)
2/7 (28.6) p = 1 † 3/7(42.9) p = 0.5† 7/10(70)
White cell count (x109/L) 7 (6.3–8.5) p = 0.2* 5.8(5.5–6.2) p = 0.3* 6.7(5.8–8.5)
C-reactive protein (mg/L) 13(6.3–21.3) Available
from 5/7 patients
p = 0.8* 10(4–13) Available from
5/7 patients
p = 0.04* 2(1.25–2.5) Available
from 6/7 patients
Albumin (g/L) 42(42–42) p = 0.3* 40.5(39.3–40.9) p = 0.6* 40(39–40)
Fecal calprotectin (μg/g) 180(110–370)
Available from 7/7
patients
p = 0.2* 1(1–60.8) Available
from 3/7 patients
p = 1* 1(1–220.8) Available
from 3/10 patients
doi:10.1371/journal.pone.0123028.t002
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study demonstrates feasibility of high-throughput, automated serum N-glycan profiling studies
that in future may be used as part of a biomarker discovery system.
Several studies have shown significant variation in glycans between healthy individuals
within the sample population.[23] In the context of disease, temporal changes in the glycan
profile have been noted for the same individual over both short and long periods of time.[3]
However in healthy individuals, the N-glycan profile is relatively stable for up to five days.[24]
The aforementioned study noted that certain glycans demonstrated greater inter-individual
variability than others.[24] Given the large number of factors that can affect the glycan profile,
this study demonstrates that three different methods of sample handling used did not signifi-
cantly affect the N-glycan profile. Several elements of the serum collection tube are known to
affect various clinical biochemical assays.[9] The present study suggests that factors including
clot activators and gel separator medium do not profoundly affect the serum glycan profile.
The strengths of this study include the combination of both quantitative and qualitative
methods to compare the glycan profile within- and between individuals. Unsupervised, unbi-
ased, quantitative methods such as hierarchical clustering and multidimensional scaling plots
accurately clustered samples from the same individual together. Blinded qualitative assessment
confirmed that chromatograms could easily be matched ‘by eye’. In the quantitative analyses,
Fig 2. Fluorescence chromatogram showing a 2-aminobenzamide labeled glucose homopolymer (GHP) run on a UHPLC HILIC column. Fig 2A–2C
and 2D–2F are derived from different patients respectively. Peaks are labeled arbitrarily in order from 1 to 42, with glucose unit values according to Guile et al
[22] Peaks are colored alternately to aid identification.
doi:10.1371/journal.pone.0123028.g002
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the chromatogram was considered in its entirety and in a subsection denoting neutral glycans.
This neutral glycan area of the chromatogram consists mainly, but not entirely, of IgG associat-
ed glycans. There is large inter-individual variation in the IgG glycome in the general popula-
tion and the relative proportions of these glycans are indicative in diseases such as rheumatoid
arthritis[25,26]. We were able to demonstrate good intra-individual correlation in spite of
these changes noted in inflammatory diseases.
A second source of considerable chromatogram variation is serum glycans that terminate
in sialic acid. These nine carbon chain acidic monosaccharides which impart charge onto gly-
cans are notoriously labile under conditions of heat and acidity and much work has been done
to reduce their degradation during glycan analysis[27,28]. Incubation at a high temperature
(100°C) during the N-glycan release may result in loss of terminal sialic acid. Whilst this may
be relevant for future studies, all samples were treated uniformly prior to comparison this
methodological study. Variations in sialic acid groups are often seen in common human dis-
eases[29]; it is therefore important to ensure that technical variation does not interfere with the
ability to compare such data. This study suggests that for sialylation, as with neutral glycans,
Fig 3. Clustering correlation complete linkage a) Neutral glycans b) Total glycans. Samples from the same individual are labeled using the same letter.
doi:10.1371/journal.pone.0123028.g003
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differences between individuals were much greater than between differently processed samples
from the same individual (S3 Fig).
Several limitations of the present study should be noted. Very small peaks were excluded,
but the smallest of the included peaks still exhibited a relatively high coefficient of variation.
Minimal intra-individual variation was noted between the three sampling methods used in this
study, however the number of included samples was relatively small and there is a risk of type
II error. Moreover, the findings of this study may not be generalisable to other serum tube/pro-
cessing methods. Future studies should compare multiple post-collection processing methods
using broader ranges of centrifugation speed and time, serum coagulation time and tempera-
ture. Significantly, this study does not address technical variation introduced by different peo-
ple processing samples nor variation between centers.
This study did not aim to compare glycan profiles between cases and control, nor infer any
biological consequence of the differences in glycans observed. This study was not powered to
detect glycan differences between cases and controls. Larger case-control studies have been
published [7] and international consortia are working towards addressing this question(www.
ibdbiom.eu). Only patients with IBD were included in this study; it is unclear whether the find-
ings would be applicable to serum N-glycan profiling in other inflammatory conditions. How-
ever, this study did demonstrate that measurement of serum glycans is robust to variation in
sample processing in IBD patients as well as controls.
Conclusion
The three different serum sample tubes processed using the described methods cause minimal
inter-individual variation in serum whole N-glycan profile when processed using an automated
Fig 4. Principal coordinate analysis plot using classical multidimensional scaling of the (1−|Pearson’s r|) distance matrix for a) Neutral serumN-
glycans b) Total serumN-glycans (CD: Crohn’s disease; UC: Ulcerative colitis; IBD: Inflammatory bowel disease).
doi:10.1371/journal.pone.0123028.g004
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Table 3. Mean peak areas, coefficients of variation for peaks and tests of glycans against tube type.
Neural
Peak GU Geometric mean % peak area Mean CV % P
1 5.89 0.13 14.22 1.00
2 5.98 1.54 4.34 1.00
3 6.19 0.85 3.19 1.00
4 6.32 0.35 8.77 1.00
5 6.61 0.09 24.91 1.00
6 6.75 1.50 3.65 1.00
7 6.88 0.58 4.89 1.00
8 6.99 0.59 3.32 1.00
9 7.07 1.27 2.10 1.00
10 7.25 0.39 10.99 1.00
11 7.42 0.06 51.62 1.00
12 7.65 1.26 3.42 1.00
13 7.72 0.36 6.18 1.00
14 7.81 0.45 7.93 1.00
15 8.04 1.19 5.27 1.00
16 8.15 0.37 11.24 1.00
Charged
Peak GU Geometric mean % peak area Mean CV % P
17 8.49 8.05 1.36 0.62
18 8.64 0.18 21.38 1.00
19 8.75 0.76 4.14 1.00
20 8.90 4.05 1.82 1.00
21 9.13 2.19 5.99 1.00
22 9.37 4.39 1.12 0.77
23 9.55 1.35 4.47 1.00
24 9.77 36.29 2.29 1.00
25 9.93 0.52 9.73 1.00
26 10.16 5.33 1.31 1.00
27 10.30 2.37 1.39 1.00
28 10.44 1.20 2.77 1.00
29 10.55 0.29 9.37 1.00
30 10.70 0.08 39.01 1.00
31 10.88 1.14 5.83 1.00
32 11.05 0.61 7.26 1.00
33 11.26 0.91 5.94 1.00
34 11.40 0.24 13.61 1.00
35 11.51 0.30 12.72 1.00
36 11.65 5.91 2.24 1.00
37 11.79 0.46 7.27 1.00
38 11.95 0.55 6.02 1.00
39 12.09 2.32 2.20 1.00
40 12.17 6.05 3.28 1.00
41 12.38 0.62 6.19 1.00
42 12.50 0.79 7.48 1.00
Rows where geometric mean peak area >1% are highlighted in bold. CV = Coefﬁcient of variation, calculated on log-transformed data. P = Bonferroni-
corrected p value from analysis of variance (ANOVA) against sample type with patient of origin as a blocking factor.
doi:10.1371/journal.pone.0123028.t003
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workstream. This has important implications for N-glycan biomarker discovery studies using
different serum processing standard operating procedures.
Supporting Information
S1 Table. Complete chromatogram dataset. Patients are labeled A to X, with each patient
having between 2 and 3 samples denoted by the letter. Data is expressed as area under each of
the 42 chromatogram peaks defined using the perpendicular drop method. Serum N-glyans are
split into neutral (peaks 1–16) and charged (peaks 17–42).
(XLSX)
S2 Table. Pairwise Correlation of samples using Pearson's Correlation Coefficient of %
area under peak.
(XLSX)
S1 Fig. Overlaid chromatograms from A.Whole Serum N-glycan profile pooled human plas-
ma repeated 24 times and B. Pooled human IgG glycan repeated 48 times.
(PDF)
Table 4. Qualitative matching of chromatograms.
Chromatogram group Galactosylation Class Sample name Diagnosis
1 LGal NGal NGal G3 G1 G2 CD
2 MLGal MLGal MLGal R1 R3 R2 UC
3 LGal LGal HGal N1 V1 L3 -
4 NGal NGal NGal I1 I2 I3 CD
5 LGal LGal U2 U3 UC
6 NGal LGal NGal Q2 Q1 Q3 CD
7 NGal NGal NGal K2 K3 K1 SC
8 MLGal MLGal LGal T2 T3 T1 CD
9 HGal HGal HGal H3 H2 H1 UC
10 HGal HGal HGal D1 D3 D2 SC
11 HGal NGal S1 S3 SC
12 MLGal MLGal X1 X3 UC
13 LGal LGal LGal C1 C3 C2 UC
14 MLGal MLGal LGal J3 J1 N3 -
15 MHGal MHGal MHGal P1 E1 E3 -
16 HGal HGal HGal O3 O2 O1 SC
17 HGal HGal HGal B1 B3 B2 UC
18 LGal MLGal MLGal W1 W2 W3 UC
19 HGal LGal LGal L1 V3 V2 CD
20 MLGal MLGal LGal A1 A3 A2 UC
21 HGal HGal HGal M2 M1 M3 SC
22 MLGal MLGal F1 F3 CD
23 HGal P3 SC
Samples that failed to be matched correctly are highlighted in italics. NGal: Proﬁle similar to normal human gamma globulin; HGal: Higher galactosylation;
MHGal: Much higher galactosylation; LGal: Lower galactosylation; MLGal: Much lower galactosylation CD: Crohn’s disease; UC: Ulcerative colitis; SC:
Symptomatic control.
doi:10.1371/journal.pone.0123028.t004
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S2 Fig. Chromatograms from each sample analysed.
(PDF)
S3 Fig. Boxplots of each individual glycan by sample type, with p values from analysis of
variance. GP = Glycan peak.
(PDF)
S1 Data. Reproducibility Whole plasma N-glycan chromatogram raw data.
(ZIP)
S2 Data. Reproducibility Whole plasma IgG chromatogram raw data.
(ZIP)
S3 Data. Serum Tube comparison Whole serum N-glycan raw data.
(ZIP)
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